

1 **Title page**

2

3 **SARS-CoV-2 seroprevalence in the municipality of São Paulo, Brazil, ten**
4 **weeks after the first reported case**

5

6 Short title: **SARS-CoV-2 seroprevalence in Sao Paulo**

7

8 **Authors**

9 Beatriz H. Tess¹, Celso F. H. Granato^{2,3}, Maria Cecília Goi Porto Alves.⁴, Maria
10 Carolina Pintao², Edgar Rizzatti², Marcia C. Nunes⁵, Fernando C. Reinach⁶

11

12

13

14 **Affiliations**

15

16 ¹Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade
17 de São Paulo, São Paulo, Brasil

18 ²Divisão de Pesquisa e Desenvolvimento, Grupo Fleury, São Paulo, Brasil

19 ³Departamento de Medicina, Disciplina de Doenças Infecciosas, Escola

20 Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brasil

21 ⁴Instituto de Saúde da Secretaria de Saúde do Estado de São Paulo, São
22 Paulo, Brasil

23 ⁵Ibope Inteligência, São Paulo, Brasil

24 ⁶Past affiliation: Departamento de Bioquímica, Instituto de Química,

25 Universidade de São Paulo; no current affiliation, São Paulo, Brasil

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Abstract** (word count 100)

27

28 A population-based household survey was performed to estimate the prevalence
29 of IgM and IgG to SARS-CoV-2 in residents of six districts in São Paulo City,
30 Brazil. Serum samples collected from 299 randomly-selected adults and 218
31 cohabitants (N=517) were tested by chemiluminescence immunoassay ten
32 weeks after the first reported case. Weighted overall seroprevalence was 4.7%
33 (95% CI 3.0-6.6%). The low seroprevalence suggests that most of this population
34 could still be infected. Serial serosurveys were initiated aiming to monitor the
35 progress of the ongoing pandemic throughout the entire city. This may help
36 inform public health authority decisions regarding prevention and control
37 strategies.

38

39

40

41 **Keywords:** COVID-19, SARS-CoV-2, epidemiological survey, adult, serological
42 test, Immunoglobulin M; Immunoglobulin G, Brazil

43

44

45 **Main text** (word count 1705)

46 **Introduction**

47 The spread of the infection with the severe acute respiratory syndrome
48 coronavirus 2 (SARS-CoV-2) has been continuing worldwide since December
49 2019. In Brazil, the first laboratory-confirmed case was reported on February 26,
50 2020. The patient was a 61-year-old male resident in São Paulo City, who had
51 returned from a visit to Lombardy (Italy) a few days previously [1]. On March 13th,
52 2020, the Brazilian Ministry of Health declared that community transmission had
53 been established as a scaling up of cases of COVID-19 had been observed in
54 multiple sites in the country and on March 24, the State of Sao Paulo declared a
55 statewide quarantine. Highly urbanized with a population of approximately 11.6
56 million people and a high level of socioeconomic inequality, São Paulo City has
57 been the epicenter of the COVID-19 epidemics in Brazil since then, registering
58 560 cases per 100.000 inhabitants, compared to the national figure of 249 cases
59 per 100.000 as of 31 May 2020 [2].

60 Due to an extremely low testing capacity, epidemic projections and policies
61 addressing COVID-19 in Brazil have been designed without robust data to inform
62 epidemic parameters. Seroprevalence surveys are important for measuring the
63 proportion of the general population who have been infected and have produced
64 SARS-CoV-2 antibodies [3], which in turn, may confer protection (at least in the
65 short term) against the infection.

66 We report results from a population-based household serosurvey planned to
67 determine the prevalence of antibodies to SARS-CoV-2 in adults in six districts
68 in São Paulo City, Brazil. We also investigated possible associations between

69 selected risk factors for SARS-CoV-2 infection and the presence of SARS-CoV-
70 2 antibodies.

71

72 **Methods**

73 The design of this cross-sectional population-based study was designed informed
74 by the World Health Organization (WHO) protocol for population-level COVID-19
75 antibody testing [4].

76 Study population and study ethics

77 Six administrative districts of the São Paulo municipality were selected for the
78 study because they were the most affected with COVID-19 according to official
79 numbers of confirmed cases and suspected or confirmed deaths per 100.000
80 habitants as of April 23, 2020 [5]. Overall, 298.240 inhabitants aged 18 years old
81 or more live in these districts [6].

82 All adults aged 18 years or older who were capable of understanding the
83 information provided by the research teams were eligible to participate. A sample
84 size of 500 households, one person per household, was planned to allow the
85 estimation of the prevalence of seropositivity greater than 4% to be obtained
86 under coefficients of variation of less than 30%. To allow for non-contact and
87 refusals, 1049 households were randomly selected and surveyed.

88 Between May 4 and May 12 2020, field teams approached all households and
89 randomly selected one member from each household. After providing written and
90 verbal information on the study, the team invited the selected resident to
91 participate. After obtaining informed consent from the participant, the team

92 applied a structured questionnaire to gather information on sociodemographic
93 characteristics and occurrence of COVID-19-related symptoms in the previous
94 two weeks. Blood was collected by venipuncture following the interview. Other
95 household members (cohabitants) who were interested in participating in the
96 study, followed the same procedures. The study was approved by the Fleury
97 Institutional Ethical Committee (CAAE 31032620.0.0000.5474).

98 Specimen collection and laboratory tests

99 Samples were transported from the collection sites to the Serology Laboratory of
100 Grupo Fleury where they were separated by centrifugation, aliquoted, and stored
101 frozen until analysis, shortly after collection. All sera were tested for the presence
102 of SARS-CoV-2 specific antibodies using the commercial kits “MAGLUMI IgM
103 2019-nCoV” and “MAGLUMI IgG 2019-nCoV” (chemiluminescence
104 immunoassay-CLIA) supplied by Bioscience Co (China National Medical
105 Products Administration: approval numbers 20203400183 (IgG) and
106 20203400182 (IgM); and Brazilian ANVISA RE 860 and 861/2020).

107 CLIA for IgG and IgM detection was developed based on a double-antibody
108 sandwich immunoassay. The recombinant antigens containing the nucleoprotein
109 and a peptide from the spike protein of SARS-CoV-2 were conjugated with FITC
110 and immobilized on anti-FITC antibody-conjugated magnetic particles. Alkaline
111 phosphatase-conjugated anti-human IgG and IgM was used as the detection
112 antibody. The tests were conducted on an automated magnetic
113 chemiluminescence analyzer (Axceed 260, Bioscience) according to the
114 manufacturer’s instructions. The antibody titer was tested once per serum
115 sample.

116 Detecting IgM and IgG antibodies against SARS-CoV-2 depends on the number
117 of days after the onset of symptoms. The diagnostic performance of CLIA has
118 been evaluated in the literature [7-11]. Although the sensitivity and specificity
119 improve during the progression of infection, sensitivity for IgM is 100% and
120 specificity 94.1% twenty days after symptoms onset. The IgG sensitivity and
121 specificity, twenty days after the onset of symptoms is 100% and 99.5%
122 respectively [7].

123 To determine the reference values, samples from patients diagnosed with the
124 COVID-19 RT-PCR test and samples from control groups such as blood donors,
125 employees without flu symptoms vaccinated in 2020, a panel of samples that
126 tested positive for other non-SARS-CoV-2 respiratory viruses, and samples from
127 carriers of other infectious diseases were used. The results of analyzing of these
128 samples led to the following reference values: IgG: reagent >1.1 UA/mL,
129 indeterminate 0.9 to 1.1 UA/mL, non-reagent <0.9 UA/mL; and IgM: reagent >1.0
130 UA/mL, indeterminate 0.7 to 1.0 UA/mL, non-reagent <0.7 UA/mL. Individuals
131 who were reactive to either IgM or IgG were considered positive.

132 Data analysis

133 Prevalence estimates were obtained for two groups separately: randomly-
134 selected residents and cohabitants. Data were analyzed for both groups and
135 were weighted according to the sampling design, which in turn, were adjusted
136 considering response rates and post-stratification by age and sex, according to
137 the district population structure in 2020 [6]. Prevalence estimates with 95%
138 confidence intervals (CI) were calculated for selected characteristics, and
139 frequency distributions of self-reported symptoms were compared between

140 seropositive and seronegative individuals. Differences in proportions were
141 assessed by the design-based F test. A p-value < 0.05 was considered to be
142 statistically significant. Indeterminate results were included as negative in the
143 analyses. STATA version 14 (StataCorp, College Station, TX, USA) was used for
144 all statistical analyses.

145 **Results**

146 Out of 771 contacted households, 299 (38.5% participation rate) randomly-
147 selected residents agreed to participate in the study, as did 218 cohabitants. The
148 seroprevalence for SARS-CoV-2 was 4.8% (95%CI 2.6-7.0%) for selected
149 residents and overall seroprevalence, including test results for the 218 voluntary
150 cohabitants, was 4.7% (95%CI 3.0-6.6%).

151 Of the 27 SARS-CoV-2 seropositive individuals, 20 were IgG positive/IgM
152 negative, six were IgG negative/IgM positive, and one was IgG positive/IgM
153 positive.

154 Socio-demographic characteristics of all 517 tested people stratified by SARS-
155 CoV-2 seroprevalence estimates are shown in Table 1. Briefly, 54.9% were
156 female, 52% aged between 18 and 44 years, 65% self-reported as being white
157 and 46.4% had a university degree (16 years or more of schooling). Comparisons
158 of seroprevalence show that people who reported brown and black skin color
159 presented significantly higher SARS-CoV-2 seroprevalence compared to those
160 with white skin. Nine or more years of schooling was associated with lower
161 seroprevalence than low education level. Participants who reported one or more
162 SARS-CoV-2-related symptoms in the past two weeks showed higher
163 seropositivity than asymptomatic people, but this difference was not statistically
164 significant (6.7% vs. 3.5%; P = .0801).

165 Frequencies of self-reported symptoms during the two-week-period before the
166 survey stratified by SARS-CoV-2 seroreactivity are shown in Table 2. Twelve
167 (45.3%) of the 27 seropositive individuals did not report symptoms. SARS-CoV-
168 2-seropositive individuals were significantly more likely to experience symptoms
169 such as fatigue, diarrhea, ageusia, and anosmia than seronegative residents.
170 None of the seropositive individuals reported previous diagnoses of infection.

171 **Discussion**

172 There are limited data available on the seroprevalence of SARS-CoV-2 infection
173 in Brazil. In this study, an overall seroprevalence for anti-SARS-CoV-2 of 4.7%
174 was observed. This estimate probably reflects the upper limit in the city of São
175 Paulo since the selected districts were those with the highest number of cases
176 and deaths in the city. One study, which used the Wondfo rapid antibody test,
177 found a SARS-CoV-2 seroprevalence of 3.1% on May 17 [12]. Our findings were
178 similar to this study, although seroprevalence estimates should be compared with
179 caution, as the representativeness of the population covered, and laboratory
180 testing methods differed between studies.

181 Besides assessing the magnitude of the pandemic in chosen areas of São Paulo
182 City, we looked at possible associations between selected risk factors for SARS-
183 CoV-2 infection and the presence of SARS-CoV-2 antibodies. Previous reports
184 have linked SARS-CoV-2 infections with no or minor symptoms [1,13,14]. We
185 found results in the same direction, 45.3% of seropositive individuals reported no
186 symptoms in the two weeks before the survey. Similar to studies on the frequency
187 of SARS-CoV-2-related symptoms, anosmia, ageusia, fatigue and diarrhea were

188 symptoms associated with seropositivity [13,14]. It is noteworthy that SARS-CoV-
189 2-related clinical symptoms and signs remain poorly documented in Brazil.

190 The strengths of the current research are that it is the first household population-
191 based serosurvey in Brazil using a chemiluminescence assay, a very precise
192 technique to detect immunoglobulins against SARS-CoV-2. This test together
193 with the probabilistic sampling design provided a clear picture of the extent of
194 human exposure to SARS-CoV-2 in the studied regions.

195 There are some limitations to the study. First, since it was a cross-sectional study,
196 temporal associations cannot be established and data are lacking on variables
197 related to the epidemiology of SARS-CoV-2, such as the history of exposure and
198 severity of symptoms. Second, refusal bias may have been introduced as a result
199 of non-response, which occurred mainly due to non-cooperation by the managers
200 of some residential blocks and to residents' unwillingness to donate blood. Third,
201 we have not included children or young people under 18 years due to logistic
202 restrictions. Last, the statistical power may have been insufficient to detect
203 differences between subgroups. However, we believe that these issues have not
204 affected our findings significantly, considering that our results are consistent with
205 several worldwide reports that showed low prevalence of SARS-CoV-2 infection
206 in the general population even in highly affected regions [12,13,15].

207 In conclusion, the overall exposure to SARS-CoV-2 in the general population in
208 the research areas is low, indicating that a significant proportion of this population
209 could still be infected. Following these initial results, a series of six monthly point-
210 prevalence serosurveys, using similar methodology and the same testing
211 method, has been initiated. By monitoring the SARS-CoV-2 seroprevalence in a
212 population-representative sample, as well as the ongoing pandemic in São Paulo

213 City, high-risk groups and areas may be identified which will help guide public
214 health actions.

215

216 **Acknowledgments**

217 We thank study participants whose cooperation made the study possible. We
218 thank Pedro Passos, Guilherme Passos, Carlos Marinelli, A. Hernandez, A.
219 Resende, D. Freitas, Fernando Pieroni, Jefferson Tolentino, Assis, L. S. Silva,
220 V.A. Frascini, Willian Malfatti, Rosi Rosendo, Helio Neves, Sofia Reinach and
221 Adriano Borges Costa for their help. We are grateful for the support of Dr Carolina
222 dos Santos Lazari.

223

224 **References**

- 225 1. Rodriguez-Morales AJ, Gallego V, Escalera-Antezana JP, et al. COVID-
226 19 in Latin America: The implications of the first confirmed case in Brazil.
227 Travel Med Infect Dis doi: 10.1016/j.tmaid.2020.101613.
- 228 2. Prefeitura do município de São Paulo, Secretaria da Saúde, Boletim
229 Diário Covid-19. Number 66 on 31 May 2020 [Portuguese]. Available at:
230 [https://www.prefeitura.sp.gov.br/cidade/secretarias/upload/saude/202005](https://www.prefeitura.sp.gov.br/cidade/secretarias/upload/saude/20200531_boletim_covid19_diario.pdf)
231 [31_boletim_covid19_diario.pdf](https://www.prefeitura.sp.gov.br/cidade/secretarias/upload/saude/20200531_boletim_covid19_diario.pdf). Accessed 10 June 2020.
- 232 3. Goudsmit J. The paramount importance of serological surveys of SARS-
233 CoV-2 infection and immunity [published online ahead of print, 21 April
234 2020]. Eur J Epidemiol doi:10.1007/s10654-020-00635-2.

- 235 4. Population-based age-stratified seroepidemiological investigation
236 protocol for COVID-19 virus infection.
237 [https://www.who.int/publicationsdetail/population-based-age-stratified-](https://www.who.int/publicationsdetail/population-based-age-stratified-seroepidemiological-investigation-protocol-for-covid-19-virus-infection)
238 [seroepidemiological-investigation-protocol-for-covid-19-virus](https://www.who.int/publicationsdetail/population-based-age-stratified-seroepidemiological-investigation-protocol-for-covid-19-virus-infection) infection.
239 Accessed 8 April 2020.
- 240 5. Prefeitura do município de São Paulo, Secretaria da Saúde, Boletim
241 Quinzenal Covid-19. Number 3 on 30 April 2020 [Portuguese].
242 [https://www.prefeitura.sp.gov.br/cidade/secretarias/upload/saude/PMSP](https://www.prefeitura.sp.gov.br/cidade/secretarias/upload/saude/PMSP_SMS_COVID19_Boletim%20Quinzenal_20200430.pdf)
243 [SMS_COVID19_Boletim%20Quinzenal_20200430.pdf](https://www.prefeitura.sp.gov.br/cidade/secretarias/upload/saude/PMSP_SMS_COVID19_Boletim%20Quinzenal_20200430.pdf). Accessed 30
244 April 2020.
- 245 6. Fundação SEADE. Perfil dos municípios paulistas, 2020 [Portuguese].
246 <https://perfil.seade.gov.br/?#>. Accessed 30 April 2020.
- 247 7. Long Q, Liu B, Deng H, et al. Antibody responses to SARS-CoV-2 in
248 patients with COVID-19. Nature Med doi: 10.1038/s41591-020-0897-1.
- 249 8. Jin Y, Wang M, Zuo Z, et al. Diagnostic value and dynamic variance of
250 serum antibody in coronavirus disease 2019. Int J Infect Dis doi:
251 10.1016/j.ijid.2020.03.065.
- 252 9. Lippi G, Salvagno GL, Pegoraro M, et al. Assessment of immune response
253 to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM
254 chemiluminescence immunoassays. Clin Chem Lab Med 2020; 58:1156-
255 9.
- 256 10. Plebani M, Padoan A, Negrini D, Carpinteri B, Sciacovelli L. Diagnostic
257 performance and thresholds: The key to harmonization in serological
258 SARS-CoV-2 assays? Clinica Chimica Acta 2020; 509:1-7.

- 259 11. Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. Analytical
260 performance of a chemiluminescence immunoassays for SARS-CoV-2
261 IgM/IgG and antibody kinetics. Clin Chem Lab Med 2020; 58:1081-8.
- 262 12. Hallal PC, Hartwig FP, Horta BL, et al. Remarkable variability in SARS-
263 CoV-2 antibodies across Brazilian regions: nationwide serological
264 household survey in 27 states. medRxiv 2020.05.30.20117531. doi:
265 10.1101/2020.05.30.20117.
- 266 13. Tu H, Tu S, Gao A, Sheng J. Current epidemiological and clinical
267 features of COVID-19; a global perspective from China. J Infect 2020;
268 81:1-9.
- 269 14. Centers for Disease Control and Prevention (CDC) USA, 2020.
270 Symptoms of novel coronavirus (2019-nCoV) on 2 June.
271 [https://www.cdc.gov/coronavirus/2019-ncov/symptoms-](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html)
272 [testing/symptoms.html](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html). Accessed 10 June 2020.
- 273 15. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-
274 CoV-2 IgG. [published online ahead of print, 11 June 2020]. Lancet doi:
275 10.1016/ S0140-6736(20)31304-0.
276
277

278 Footnote page

279

280 *Conflict of interests Statement:* Authors associated with Grupo Fleury (C.F.H.G.,
281 M.C.P., E.R.) and Ibope Inteligência (M.C.N.) disclose the following potential
282 conflict of interest: the two organizations are co-funding the project by providing
283 their services at or below cost. These include data and blood sample collection
284 and laboratory tests. The companies sell these services in the market and might
285 profit from the publicity generated by the results of this research.

286 B.H.T., M.C.G.P.A. and F.C.R. declare no conflict of interest.

287

288 *Funding Statement:* The study received funding from Instituto Semeia, Grupo
289 Fleury and Ibope Inteligência.

290

291 **# Corresponding author:**

292 Beatriz H. Tess, MD, PhD

293 Departamento de Medicina Preventiva

294 Faculdade de Medicina da USP

295 Av. Dr. Arnaldo, 455, 2º andar

296 01246-903 São Paulo, SP, Brasil

297 Tel.: (+ 55 11) 3061 7082

298 E-mail: beatriz.tess@usp.br

299

300 *Availability of data and materials:* The datasets analyzed during the current
301 study are available from the corresponding author on reasonable request.

302 Table 1. SARS-CoV-2 seroprevalence, and 95% confidence interval, by selected
 303 population characteristics

Characteristic	N of adults	Seroprevalence*		<i>p value</i> **
		%	95%CI	
Overall	517	4.7	3.0 - 6.6	-
Gender				
Female	284	4.2	2.2 – 7.8	0.5821
Male	233	5.4	3.1 – 9.2	
Age (years)				
18-44	269	4.3	2.5 – 7.3	0.5916
≥ 45	248	5.2	3.1 – 8.5	
Skin colour/race***				
White	335	3.3	1.9 – 5.6	0.0495****
Brown and black	147	8.6	4.7 – 15.0	
Asian and indigenous	30	3.5	0.5 - 22.5	
Education (years of schooling)				
≤8	59	11.6	5.4 – 23.0	0.0251****
9-15	218	4.1	2.2 – 7.2	
≥16	240	3.6	1.9 – 6.8	
SARS-CoV-2 related symptoms in the past				
2 weeks				
No symptom reported	312	3.5	2.1 – 5.8	0.0801
One or more symptoms reported	205	6.7	3.8 – 11.7	

304 *corrected for sample design

305 **design-based F test

306 *** missing data (n=5)

307 **** significant at 5%

308 Table 2: Frequency distribution, and 95% confidence interval, of self-reported
 309 symptoms in the last 14 days from date of survey by result of SARS-CoV-2
 310 seroreactivity
 311

Symptoms*	Seronegative			Seropositive			p value**
	n	%	95%CI	n	%	95%CI	
Overall	190	37.5	32.8 – 42.4	15	54.7	35.5 – 72.6	0.0801
Fever	10	2.1	0.9 - 4.8	2	5.6	1.2 - 22.0	0.2525
Cough	79	15.4	12.1 - 19.4	6	20.6	9.4 – 39.4	0.4556
Shortness of breath	24	4.7	2.7 – 7.9	2	5.6	1.2 – 22.0	0.7492
Sore throat	46	9.3	7.3 – 11.7	3	8.1	2.5 – 23.5	0.8226
Rhinorrhea	107	21.0	17.1 – 25.5	7	25.5	12.5 – 45.2	0.5827
Fatigue	32	5.8	3.6 – 9.3	5	20.3	8.5 – 41.2	0.0040***
Myalgia	46	8.9	6.2 – 12.7	6	18.8	8.3 – 37.1	0.0528
Diarrhea	28	5.5	3.7 – 8.0	4	13.2	5.3 – 29.0	0.0408***
Ageusia	14	2.9	1.6 – 5.3	6	18.4	7.1 – 39.7	0.0003***
Anosmia	15	3.0	1.7 – 5.4	6	18.4	7.1 – 39.7	0.0002***

312

313 * single or multiple symptoms

314 **design-based F test

315 *** significant at 5%